Celldex Therapeutics Statistics
Share Statistics
Celldex Therapeutics has 66.39M
shares outstanding. The number of shares has increased by 0.72%
in one year.
| Shares Outstanding | 66.39M |
| Shares Change (YoY) | 0.72% |
| Shares Change (QoQ) | 0.06% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,312 |
| FTD / Avg. Volume | 0.55% |
Short Selling Information
The latest short interest is 9.01M, so 13.57% of the outstanding
shares have been sold short.
| Short Interest | 9.01M |
| Short % of Shares Out | 13.57% |
| Short % of Float | 16.03% |
| Short Ratio (days to cover) | 14.05 |
Valuation Ratios
The PE ratio is -10.31 and the forward
PE ratio is -5.13.
Celldex Therapeutics's PEG ratio is
0.64.
| PE Ratio | -10.31 |
| Forward PE | -5.13 |
| PS Ratio | 231.8 |
| Forward PS | 1.8 |
| PB Ratio | 2.18 |
| P/FCF Ratio | -10.19 |
| PEG Ratio | 0.64 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Celldex Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.91,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 18.91 |
| Quick Ratio | 18.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $37,741.94 |
| Profits Per Employee | $-848,725.81 |
| Employee Count | 186 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -50.22% in the
last 52 weeks. The beta is 1.39, so Celldex Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.39 |
| 52-Week Price Change | -50.22% |
| 50-Day Moving Average | 19.19 |
| 200-Day Moving Average | 26.94 |
| Relative Strength Index (RSI) | 51.44 |
| Average Volume (20 Days) | 778,404 |
Income Statement
In the last 12 months, Celldex Therapeutics had revenue of 7.02M
and earned -157.86M
in profits. Earnings per share was -2.45.
| Revenue | 7.02M |
| Gross Profit | 3.84M |
| Operating Income | -195.08M |
| Net Income | -157.86M |
| EBITDA | -154.69M |
| EBIT | -195.08M |
| Earnings Per Share (EPS) | -2.45 |
Full Income StatementBalance Sheet
The company has 28.36M in cash and 3.81M in
debt, giving a net cash position of 24.54M.
| Cash & Cash Equivalents | 28.36M |
| Total Debt | 3.81M |
| Net Cash | 24.54M |
| Retained Earnings | -1.56B |
| Total Assets | 792.34M |
| Working Capital | 707.66M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -157.78M
and capital expenditures 0, giving a free cash flow of -159.7M.
| Operating Cash Flow | -157.78M |
| Capital Expenditures | n/a |
| Free Cash Flow | -159.7M |
| FCF Per Share | -2.48 |
Full Cash Flow StatementMargins
Gross margin is 54.74%, with operating and profit margins of -2778.89% and -2248.76%.
| Gross Margin | 54.74% |
| Operating Margin | -2778.89% |
| Pretax Margin | -2248.76% |
| Profit Margin | -2248.76% |
| EBITDA Margin | -2203.5% |
| EBIT Margin | -2778.89% |
| FCF Margin | -2274.89% |
